The long-term treatment of panic disorder

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL.8, 1998, Pages 17-23

  Davidson, Jonathan R T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOMIPRAMINE; IMIPRAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CHRONIC DISEASE; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; PANIC; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TREATMENT PLANNING;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; CLOMIPRAMINE; COGNITIVE THERAPY; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; PANIC DISORDER; PAROXETINE; RECURRENCE; RELAXATION TECHNIQUES; TREATMENT OUTCOME;

EID: 0031903652     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Pollack MH, Smoller W. The longitudinal course and outcome of panic disorder Psychiatr Clin North Am 1995;18:785-801
2. Noyes R Jr, Garvey MJ, Cook BL, et al. Problems with tricyclic use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989;50:163-169
3. Nagy LM, Krystal JH, Woods SW, et al. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. Arch Gen Psychiatry 1989;46:993-999
4. Noyes R Jr, Garvey MJ, Cook BL. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord 1989;16:249-257
5. Katschnig H, Amering MA, Stolk JM, et al. Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry 1995;167:487-494
6. Roy-Byrne PP, Cowley DS. Course and outcome in panic disorder: a review of recent follow-up studies. Anxiety 1995;1:151-160
7. Burrows GD, Judd FK, Norman TR. Long-term drug treatment of panic disorder. J Psychiatr Res 1993;27(1, suppl):111-125
8. Marchesi C, Ampollini P, Signifredi R, et al. The treatment of panic disorder in a clinical setting: a 12-month naturalistic study. Neuropsychobiology 1997;36:25-31
9. Judge R, Steiner M. The longterm efficacy and safety of paroxetine in panic disorder [abstract]. Eur Neuropsychopharmacol 1996;6(3, suppl):207
10. Zitrin CM, Klein DF, Woerner MG. Behavior therapy, supportive psychotherapy, imipramine, and phobias. Arch Gen Psychiatry 1978;35:307-316
11. Clark DM, Salkovskis PM, Hackmann A, et al. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 1994;164:759-769
12. Mavissakalian M, Perel JM. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1992;49:318-323
13. Mavissakalian M, Michelson L. Two-year follow-up of exposure and imipramine treatment of agoraphobia. Am J Psychiatry 1986;143:1106-1112
14. Mavissakalian M, Perel JM. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry 1992;149: 1053-1057
15. Lecrubier Y, Judge R, and the Collaborative Paroxetine Panic Study Investigators. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand 1997;95:153-160
16. Rickels K, Schweizer E, Weiss S, et al. Maintenance drug treatment for panic disorder, II: short- and long-term outcome after drug taper. Arch Gen Psychiatry 1993;50:61-68
17. Pollack MH, Otto MW, Tesar GE, et al. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993;13:257-263
18. Abelson JL, Curtis GC. Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels. Am J Psychiatry 1996;153:69-73